Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice

References

• Institute for Health Metrics and EvaluationGlobal burden of disease (GBD) visualizationsSeattle, WAInstitute for Health Metrics and Evaluation2013 Available from: http://www.healthmetricsandevaluation.org/gbd/visualizations/countryAccessed May 15, 2013
   Google Scholar
• HammCWBassandJPAgewallSESC Committee for Practice GuidelinesESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)Eur Heart J201132232999305421873419
   PubMed Web of Science ®Google Scholar
• YusufSZhaoFMehtaSRChrolaviciusSTognoniGFoxKKClopidogrel in Unstable Angina to Prevent Recurrent Events Trial InvestigatorsEffects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevationN Engl J Med2001345749450211519503
   PubMed Web of Science ®Google Scholar
• ChenZMJiangLXChenYPCOMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative groupAddition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trialLancet200536694971607162116271642
   PubMed Web of Science ®Google Scholar
• WiviottSDBraunwaldEMcCabeCHTRITON-TIMI 38 InvestigatorsPrasugrel versus clopidogrel in patients with acute coronary syndromesN Engl J Med2007357202001201517982182
   PubMed Web of Science ®Google Scholar
• RoeMTArmstrongPWFoxKATRILOGY ACS InvestigatorsPrasugrel versus clopidogrel for acute coronary syndromes without revascularizationN Engl J Med2012367141297130922920930
   PubMed Web of Science ®Google Scholar
• WallentinLBeckerRCBudajAPLATO InvestigatorsTicagrelor versus clopidogrel in patients with acute coronary syndromesN Engl J Med2009361111045105719717846
   PubMed Web of Science ®Google Scholar
• [No authors listed]Collaborative overview of randomised trials of antiplatelet therapy – I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ CollaborationBMJ19943086921811068298418
   PubMed Web of Science ®Google Scholar
• MerliniPABauerKAOltronaLPersistent activation of coagulation mechanism in unstable angina and myocardial infarctionCirculation199490161688026047
   PubMed Web of Science ®Google Scholar
• AndreottiFTestaLBiondi-ZoccaiGGCreaFAspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patientsEur Heart J200627551952616143706
   PubMed Web of Science ®Google Scholar
• MackmanNTriggers, targets and treatments for thrombosisNature2008451718191491818288180
   PubMed Web of Science ®Google Scholar
• BorissoffJISpronkHMten CateHThe hemostatic system as a modulator of atherosclerosisN Engl J Med2011364181746176021542745
   PubMed Web of Science ®Google Scholar
• MannKGBrummelKButenasSWhat is all that thrombin for?J Thromb Haemost2003171504151412871286
   PubMed Web of Science ®Google Scholar
• De CaterinaRHustedSWallentinLEuropean Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart DiseaseGeneral mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart DiseaseThromb Haemost2013109456957923447024
   PubMed Web of Science ®Google Scholar
• TurpieAGEsmonCVenous and arterial thrombosis – pathogenesis and the rationale for anticoagulationThromb Haemost2011105458659621225099
   PubMed Web of Science ®Google Scholar
• WallentinLWilcoxRGWeaverWDESTEEM InvestigatorsOral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trialLancet2003362938678979713678873
   PubMed Web of Science ®Google Scholar
• ChristerssonCOldgrenJBylockASiegbahnAWallentinLEarly decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM TrialEur Heart J200728669269817314111
   PubMed Web of Science ®Google Scholar
• StegPGJamesSKAtarDTask Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevationEur Heart J201233202569261922922416
   PubMed Web of Science ®Google Scholar
• TestaLZoccaiGBPortoIAdjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromesAm J Cardiol200799121637164217560866
   PubMed Web of Science ®Google Scholar
• AnsellJHirshJHylekEJacobsonACrowtherMPalaretiGAmerican College of Chest PhysiciansPharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Chest20081336 Suppl160S198S18574265
   PubMed Web of Science ®Google Scholar
• ErikssonBIQuinlanDJEikelboomJWNovel oral factor Xa and thrombin inhibitors in the management of thromboembolismAnnu Rev Med201162415721226611
   PubMed Web of Science ®Google Scholar
• WanatMANovel oral anticoagulants: a review of new agentsPostgrad Med2013125410311423933899
   PubMed Web of Science ®Google Scholar
• OldgrenJBudajAGrangerCBRE-DEEM InvestigatorsDabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trialEur Heart J201132222781278921551462
   PubMed Web of Science ®Google Scholar
• AlexanderJHBeckerRCBhattDLAPPRAISE Steering Committee and InvestigatorsApixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trialCirculation2009119222877288519470889
   PubMed Web of Science ®Google Scholar
• AlexanderJHLopesRDJamesSAPPRAISE-2 InvestigatorsApixaban with antiplatelet therapy after acute coronary syndromeN Engl J Med2011365869970821780946
   PubMed Web of Science ®Google Scholar
• StegPGMehtaSRJukemaJWRUBY-1 InvestigatorsRUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndromeEur Heart J201132202541255421878434
   PubMed Web of Science ®Google Scholar
• GoldsteinSBatesEBhattDSafety evaluation of the factor Xa inhibitor TAK-442 in subjects with acute coronary syndromes: phase 2 AXIOM-ACS trial resultsEur Heart J201132Abstract Supplement Abstract P2430
   PubMedGoogle Scholar
• MegaJLBraunwaldEMohanaveluSATLAS ACS-TIMI 46 study groupRivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trialLancet20093749683293819539361
   PubMed Web of Science ®Google Scholar
• MegaJLBraunwaldEWiviottSDATLAS ACS 2–TIMI 51 InvestigatorsRivaroxaban in patients with a recent acute coronary syndromeN Engl J Med2012366191922077192
   PubMed Web of Science ®Google Scholar
• ArtangRRomeENielsenJDVidailletHJMeta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitorsAm J Cardiol2013112121973197924075284
   PubMed Web of Science ®Google Scholar
• AhrensIPeterKLipGYBodeCDevelopment and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigationDiscov Med2012137344545022742650
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMWensingGVoithBZuehlsdorfMSafety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – after multiple dosing in healthy male subjectsEur J Clin Pharmacol2005611287388016328318
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMRothAMueckWDose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjectsCurr Med Res Opin200824102757276518715524
   PubMed Web of Science ®Google Scholar
• PerzbornERoehrigSStraubAKubitzaDMisselwitzFThe discovery and development of rivaroxaban, an oral, direct factor Xa inhibitorNat Rev Drug Discov2011101617521164526
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use (CHMP)Summary of Opinion (Post Authorisation): Xarelto, rivaroxabanLondon, UKEuropean Medicines Agency2013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000944/WC500140679.pdfAccessed July 16, 2013
   Google Scholar
• MegaJLBraunwaldEWiviottSDComparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51)Am J Cardiol2013112447247823711804
   PubMed Web of Science ®Google Scholar
• PatelMRMahaffeyKWGargJROCKET AF InvestigatorsRivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med20113651088389121830957
   PubMed Web of Science ®Google Scholar
• GrangerCBAlexanderJHMcMurrayJJARISTOTLE Committees and InvestigatorsApixaban versus warfarin in patients with atrial fibrillationN Engl J Med20113651198199221870978
   PubMed Web of Science ®Google Scholar
• RakowskiTDudekDDziewierzAImpact of infarct-related artery patency before primary PCI on outcome in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trialEuroIntervention20138111307131423538158
   PubMed Web of Science ®Google Scholar
• SculpherMJLozano-OrtegaGSambrookJFondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trialAm Heart J2009157584585219376310
   PubMed Web of Science ®Google Scholar
• TurpieAGKreutzRLlauJNorrvingBHaasSManagement consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitorThromb Haemost2012108587688623014816
   PubMed Web of Science ®Google Scholar
• MehranRPocockSJNikolskyEA risk score to predict bleeding in patients with acute coronary syndromesJ Am Coll Cardiol201055232556256620513595
   PubMed Web of Science ®Google Scholar
• Bayer PharmaAGXarelto^® Summary of Product Characteristics – EUBerlin, GermanyBayer Pharma AG2013 Available from: http://www.xarelto.com/html/downloads/2013-05_XRL_SPC_final_low.pdfAccessed June 11, 2013
   Google Scholar
• PeacockWFGearhartMMMillsRMEmergency management of bleeding associated with old and new oral anticoagulantsClin Cardiol2012351273073722811404
   PubMed Web of Science ®Google Scholar
• EerenbergESKamphuisenPWSijpkensMKMeijersJCBullerHRLeviMReversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjectsCirculation2011124141573157921900088
   PubMed Web of Science ®Google Scholar
• MarluRHodajEParisAAlbaladejoPCracowskiJLPernodGEffect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteersThromb Haemost2012108221722422627883
   PubMed Web of Science ®Google Scholar
• PerzbornEGruberATinelHReversal of rivaroxaban anticoagulation by haemostatic agents in rats and primatesThromb Haemost2013110116217223636219
   PubMed Web of Science ®Google Scholar
• MarkCVandanaMMichaelKA phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for Fxa inhibitors [abstract]Blood2013122213636
   Web of Science ®Google Scholar
• DewildeWJOirbansTVerheugtFWWOEST study investigatorsUse of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trialLancet201338198721107111523415013
   PubMed Web of Science ®Google Scholar
• Bayer PharmaAGA study exploring two strategies of rivaroxaban (JNJ39039039; BAY-59-7939) and one oral vitamin K antagonist in patients with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI) Available from: http://clinicaltrials.gov/ct2/show/NCT01830543. NLM identifier: NCT01830543Accessed May 17, 2013
   Google Scholar